234 related articles for article (PubMed ID: 29394114)
1. Efficacy of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review.
MacDonald R; Brasure M; Dahm P; Olson CM; Nelson VA; Fink HA; Risk MC; Rwabasonga B; Wilt TJ
Aging Male; 2019 Mar; 22(1):1-11. PubMed ID: 29394114
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
Dahm P; Brasure M; MacDonald R; Olson CM; Nelson VA; Fink HA; Rwabasonga B; Risk MC; Wilt TJ
Eur Urol; 2017 Apr; 71(4):570-581. PubMed ID: 27717522
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
[TBL] [Abstract][Full Text] [Related]
4. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Singh DV; Mete UK; Mandal AK; Singh SK
J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
[TBL] [Abstract][Full Text] [Related]
5. Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data.
Novara G; Chapple CR; Montorsi F
BJU Int; 2015 May; 115(5):802-14. PubMed ID: 25130493
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
[TBL] [Abstract][Full Text] [Related]
7. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
Silva J; Silva CM; Cruz F
Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies.
Oelke M; Wagg A; Takita Y; Büttner H; Viktrup L
BJU Int; 2017 May; 119(5):793-803. PubMed ID: 27988986
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.
Füllhase C; Chapple C; Cornu JN; De Nunzio C; Gratzke C; Kaplan SA; Marberger M; Montorsi F; Novara G; Oelke M; Porst H; Roehrborn C; Stief C; McVary KT
Eur Urol; 2013 Aug; 64(2):228-43. PubMed ID: 23375241
[TBL] [Abstract][Full Text] [Related]
10. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis.
Gacci M; Ficarra V; Sebastianelli A; Corona G; Serni S; Shariat SF; Maggi M; Zattoni F; Carini M; Novara G
J Sex Med; 2014 Jun; 11(6):1554-66. PubMed ID: 24708055
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
Yan H; Zong H; Cui Y; Li N; Zhang Y
J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
[TBL] [Abstract][Full Text] [Related]
12. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
[TBL] [Abstract][Full Text] [Related]
13. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
Zhang J; Li X; Yang B; Wu C; Fan Y; Li H
World J Urol; 2019 Jan; 37(1):143-153. PubMed ID: 29948047
[TBL] [Abstract][Full Text] [Related]
14. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of PDE5-Is and α-1 blockers for treating lower ureteric stones or LUTS: a meta-analysis of RCTs.
Sun X; Guan W; Liu H; Tang K; Yan L; Zhang Y; Zeng J; Chen Z; Xu H; Ye Z
BMC Urol; 2018 May; 18(1):30. PubMed ID: 29724204
[TBL] [Abstract][Full Text] [Related]
16. Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.
De Nunzio C; Presicce F; Tubaro A
Drugs Today (Barc); 2016 Sep; 52(9):501-517. PubMed ID: 27883117
[TBL] [Abstract][Full Text] [Related]
17. Tadalafil - a therapeutic option in the management of BPH-LUTS.
Carson CC; Rosenberg M; Kissel J; Wong DG
Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia.
Yoshida T; Kinoshita H; Shimada S; Taguchi M; Matsuda T
Urology; 2017 Aug; 106():153-159. PubMed ID: 28431996
[TBL] [Abstract][Full Text] [Related]
19. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
